2023-11-13 14:44:00
(CercleFinance.com) – The Swiss biotechnology group Basilea Pharmaceutica announced on Monday that it would acquire rights to fosmanogepix, a broad-spectrum antifungal in the development phase, from Amplyx, a subsidiary of Pfizer.
This drug with a new mechanism of action – and which can be administered both intravenously and orally – is the subject of phase 2 studies for the treatment of candidiasis and invasive fungal infections.
David Veitch, CEO of Basilea, highlights a ‘very promising’ candidate at an advanced stage of development representing an interesting avenue for the most difficult to treat fungal infections.
Basilea says it plans to start a phase 3 clinical study in the middle of next year.
The group plans to make a milestone payment of $37 million before payments that might reach $110 million depending on the progress of the projects.
In total, its payments might reach $396 million, not including royalties on potential future sales of the drug.
Apart from fosmanogepix, Basilea has acquired the rights to another antifungal from Amplyx, this time in preclinical development.
1699888556
#Pfizer #Amplyx #transfers #rights #antifungal #Basilea #p.m
